REGN - Regeneron Pharmaceuticals Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)
2024-03-13 13:05:07 ET
Regeneron Pharmaceuticals, Inc. (REGN)
Leerink Partners Global Biopharma Conference
March 13, 2024 10:40 AM ET
Company Participants
Ryan Crowe - Vice President, Investor Relations
Christopher Fenimore - Chief Financial Officer
Conference Call Participants
David Risinger - Leerink Partners
Presentation
David Risinger
Thanks very much for being with us here today. I thought we could just start with the EYLEA franchise. Okay. We'll just jump right into it.
Ryan Crowe
Actually, David, if I could just read a forward-looking statement briefly. I'd like to remind you that, our remarks made today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risk and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Now that's out of the way, EYLEA.
Question-and-Answer Session
Q - David Risinger
All right. Thank you. I guess just to kick off, could you just comment on physician feedback so far on EYLEA HD and just frame the switching? What you're seeing in terms of from other products to HD and from EYLEA 2 mg to HD. If you could just provide the latest on that, that would be, that'd be helpful....
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)